The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I study of intermittent high-dose lapatinib alternating with capecitabine for HER2-positive breast cancer with central nervous system metastases.
 
Aki Morikawa
Research Funding - Genentech/Roche (Inst); Lilly (Inst); Merrimack (Inst); Novartis (Inst)
 
Elena Pentsova
Consulting or Advisory Role - AstraZeneca
 
Margaret Kemeny
No Relationships to Disclose
 
Sujata Patil
No Relationships to Disclose
 
Bob T. Li
Consulting or Advisory Role - Biosceptre International; Guardant Health; Mersana; Roche; Thermo Fisher Scientific
Research Funding - AstraZeneca (Inst); BioMed Valley Discoveries (Inst); GRAIL (Inst); Illumina (Inst); Roche/Genentech (Inst)
 
Kendrick Tang
No Relationships to Disclose
 
Martin Fleisher
No Relationships to Disclose
 
Catherine H. Van Poznak
Research Funding - Bayer (Inst)
Patents, Royalties, Other Intellectual Property - UpToDate
 
Larry Norton
Stock and Other Ownership Interests - Samus Therapeutics
Honoraria - Bluprint Oncology Concepts; Bristol-Myers Squibb; Celgene; Ions Pharmaceuticals; Miami Cancer Institute; Oncolytics; Pfizer; Pierian Biosciences; Sermonix Pharmaceuticals
Consulting or Advisory Role - Bluprint Oncology Concepts; Bristol-Myers Squibb; Celgene; Ions Pharmaceuticals; Miami Cancer Institute; Oncolytics; Pfizer; Pierian Biosciences; Sermonix Pharmaceuticals
Patents, Royalties, Other Intellectual Property - Memorial Sloan-Kettering Cancer Center
Travel, Accommodations, Expenses - Bluprint Oncology Concepts; Bristol-Myers Squibb; Celgene; Ions Pharmaceuticals; Miami Cancer Institute; Oncolytics; Pfizer; Pierian Biosciences; Sermonix Pharmaceuticals
 
Andrew David Seidman
Honoraria - Eisai; Genentech; Genomic Health; Nektar; Novartis; Odonate Therapeutics; Pfizer
Consulting or Advisory Role - Eisai; Genentech; Merrimack; Nektar; Odonate Therapeutics; Pfizer
Speakers' Bureau - Eisai; Genentech; Genomic Health; Novartis; Pfizer
Research Funding - Bayer (Inst); Nektar (Inst); Novartis (Inst); Odonate Therapeutics (Inst)